Clinical study to evaluate the efficacy of blood purification therapy on cholesterol crystal embolism - Clinical evaluation of blood purification therapy on CCE

Incorporated administrative agency, Japan Community Health care Organization, Sendai Hospital0 个研究点目标入组 35 人开始时间: 2012年11月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who meet any of the following criteria will be excluded. (i) Patients with contraindication to anticoagulant (Nafamostat Mesilate). (ii) Blood purification therapy is inapplicable because of severe heart failure, acute myocardial infarction, severe arrhythmia, acute stroke, or severe uncontrollable hypertension or hypotension. (iii) Patients with body weight less than 40kg. (iv) Patients with a history of allergic reaction or hypersensitivity to blood purification therapy. (v) Patients who cannot stop taking ACE inhibitors. (vi) Patients with any disease in which corticosteroid, statin are contraindicated. (vii) Patients participated in another clinical trial or study at the time of obtaining informed consent. (viii) Patients receiving chronic hemodialysis. (ix) Otherwise, patients who are judged by the investigator as being unsuitable for inclusion in the study.

发起方

Incorporated administrative agency, Japan Community Health care Organization, Sendai Hospital